{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Use of HAE attack medications over 24 weeks', 'The proportion of responders to study drug, defined as at least a 50% relative', 'reduction in the rate of investigator-confirmed HAE attacks during treatment', 'compared with the baseline attack rate', 'Treatment comparisons in the AE-QoL total score change from baseline will be analyzed using a', 'mixed model for repeated measures (MMRM) with restricted maximum likelihood estimation', 'and an unstructured covariance matrix. The estimated treatment difference for each BCX7353', 'dose-placebo at each visit will be displayed together with the 95% confidence interval and the', 'associated p-value. Primary inferences will be drawn from treatment differences for the changes', 'from baseline derived from the MMRM model at Week 24. The change from baseline in the AE-', 'QoL domain scores (function, fatigue, nutrition, and fear/shame) will also be analyzed using a', 'MMRM model.', 'The secondary and exploratory efficacy endpoints will be summarized and listed. The', 'between-treatment comparisons will be performed using the similar Poisson regression model for', 'the Investigator-confirmed HAE attacks during the effective treatment period. The between', 'treatment comparison for the responder endpoints will be performed using', \"Cochran-Mantel-Haenszel, Chi-square, or Fisher's exact test. Multiplicity adjustments for the\", 'secondary efficacy endpoints will be described in the SAP.', 'Additional related details of HAE attacks (eg, symptoms, anatomical location, hospitalizations,', 'emergency room visits, and attack duration) will be summarized and listed. Details of these', 'analyses will be provided in the SAP.', 'The efficacy endpoints for Parts 2 and 3 include:', 'Number and rate of HAE attacks', 'Durability of response (attack rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of HAE attack medications', 'Discontinuations due to lack of efficacy (through Week 48 only)', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', 'The analyses of efficacy at the end of the study will be provided descriptively. For the placebo', 'subjects switched to an active BCX7353 dose, the change from placebo to the active dosing', 'period will be summarized. The details of the planned efficacy analyses for the entire study will', 'be provided in the SAP.', '13.5.5.', 'Planned Analyses', 'A single, blinded interim analysis for the purposes of possible sample size re-estimation may be', 'performed after 50% of the subjects complete 24 weeks (See Section 13.3).', '96']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'The primary analysis is planned after the last subject completes Week 24 of the study.', 'The Sponsor and all other personnel who are blinded to study treatment will remain blinded to', 'Part 1 treatment until after the database has been locked and the primary analysis conducted.', '13.5.6.', 'Analysis of Safety Variables', 'The safety analyses will be analyzed separately for Part 1; Parts 1, 2, and 3 will be combined for', 'a long-term safety assessment.', 'Safety endpoints that will be summarized include, at a minimum, the number and proportion of', 'subjects 1) with a TEAE; 2) who discontinue BCX7353 due to a TEAE 3) who experience a', 'TESAE; 4) who experience a treatment-emergent Grade 3 or 4 AE; and 5) who experience a', 'treatment-emergent Grade 3 or 4 laboratory abnormality. In addition, the proportion of subjects', 'with a treatment-emergent, treatment-related AE consistent with a drug rash will also be', 'summarized.', 'Adverse events will be mapped to a Medical Dictionary for Regulatory Activities (MedDRA)', 'preferred term and system organ class (SOC). The occurrence of TEAEs will be summarized', 'using MedDRA preferred terms, SOC, and severity. Separate summaries of TEAEs, TESAEs,', 'AEs considered to be related to study drug, and AEs leading to study drug interruption or to', 'discontinuation will be generated. All AEs will be listed for individual subjects showing both', 'verbatim and preferred terms.', 'Descriptive summaries of vital signs, weight, bedside ECG parameters, and clinical laboratory', 'results will be presented. Laboratory abnormalities will be graded according to the DMID Adult', 'Toxicity Table (Publish Date: Draft, November 2007; Appendix 16.1).', 'Any graded abnormality that occurs following the initiation of study drug and represents at least', '1-grade increase from the baseline assessment is defined as treatment-emergent. The number and', 'percentage of subjects who experience treatment-emergent graded toxicities will be summarized.', 'Laboratory toxicity shifts from baseline to worst postbaseline assessments will be summarized.', 'Clinically significant abnormal morphological ECG findings will be summarized.', 'The change from baseline in QTcF will be determined by routine ECGs. At each time point', \"ECGs are analyzed, an individual subject's change from baseline will be calculated as:\", 'Aik= (QTcF for subject at time point k - Baseline QTcF)', 'Where QTcF measurements will be the average of triplicate ECGs at baseline and single values', 'at each time point.', 'For routine ECGs, the number and proportion of subjects with QTcF < 450, > 450 to 480,', '> 480 to 500, and > 500 msec; or changes of < 30, > 30 to < 60, or > 60 msec will be', 'summarized.', 'Physical examination findings will be listed.', 'Concomitant medications will be coded using the World Health Organization drug dictionary', 'and summarized.', 'As applicable, safety data will be summarized by treatment group and total BCX7353. No tests', 'of hypothesis are planned for safety data.', '97']\n\n###\n\n", "completion": "END"}